FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Highlight the innovative analytical techniques developed for detecting prohibited peptides in sports doping control urine samples and discuss their potential applications in clinical peptide therapy.
연구 도서관으로 돌아가기
insulingrowth hormone-releasing hormonesinsulin-like growth factors

Highlight the innovative analytical techniques developed for detecting prohibited peptides in sports doping control urine samples and discuss their potential applications in clinical peptide therapy.

May 16, 2026
Share

원본 논문

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Thomas Andreas et al.Journal of mass spectrometry : JMS2024
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

Streamlining Detection of Prohibited Peptides in Sports Doping Control: A Breakthrough in Analytical Techniques

Published: May 16, 2026 | Source: Journal of mass spectrometry : JMS (2024) | Category: insulin, growth hormone-releasing hormones, insulin-like growth factors

Overview

This paper reviews the latest advancements in chromatographic-mass spectrometric analysis for detecting peptides with molecular masses between 2 and 10 kDa in doping control urine samples. The findings highlight a significant simplification of established analytical procedures, which could enhance the efficiency and accuracy of testing for prohibited substances in sports.

Study Background

In recent years, the use of peptides as performance-enhancing drugs has risen sharply among athletes, necessitating sophisticated methods to detect these compounds. Traditional mass spectrometric techniques often require complex sample preparation steps that are not easily adaptable across different types of peptides. This study aimed to streamline existing methodologies for detecting a range of prohibited peptides in urine samples, focusing on insulin and growth hormone-releasing hormones.

What the Research Found

The researchers reviewed various chromatographic-mass spectrometric methods used for analyzing peptidic analytes between 2-10 kDa in doping control urine samples. They identified that existing techniques often require extensive sample preparation steps tailored to specific peptides, which can be time-consuming and resource-intensive. The study's key finding is the development of a simplified extraction method that efficiently isolates these peptides from urine without compromising detection accuracy.

Specifically, the paper demonstrates successful isolation and identification of various insulin types (human, lispro, aspart, glulisine, tresiba, glargine metabolite, bovine insulin, porcine insulin) along with growth hormone-releasing hormones (sermorelin, CJC-1295, tesamorelin) and their respective metabolites. The simplified method allows for a more streamlined analysis process that can be applied broadly across different types of peptides.

What This Means for Peptide Users

For athletes who use or are suspected of using prohibited peptides, this new analytical technique could lead to faster and more accurate detection methods. It may also reduce the likelihood of false negatives due to improper sample preparation. However, it is important to note that these changes primarily impact sports doping control rather than clinical settings.

Limitations and Caveats

As a review paper, this study does not present new experimental data but synthesizes existing methodologies. The focus on doping control urine samples limits its broader applicability in clinical peptide therapy or other medical contexts. Additionally, while the simplified extraction method is promising, it needs further validation across a wider range of peptides and sample types to ensure reliability.

How This Compares to Previous Research

Previous studies have focused on developing highly specific methods for individual peptides due to their unique physicochemical properties. However, these techniques often lack versatility when applied to other peptides or substances. The current study stands out by proposing a more generalized approach that can be adapted across different types of prohibited peptides in sports doping control.

Our Analysis

PeptideVault views this paper as a valuable contribution to the field of peptide detection in sports doping control. While it does not introduce entirely new methods, it effectively simplifies existing complex procedures and demonstrates their applicability across multiple peptide types. The potential for broader application in clinical settings remains an area for future research.

Key Takeaways

  • Simplified Extraction Method: A streamlined approach to isolate peptides from urine samples.
  • Versatility Across Peptides: Demonstrated effectiveness with various insulin types and growth hormone-releasing hormones.
  • Focus on Doping Control: Primarily relevant for sports doping control, with limited applicability in clinical settings.

Original Source

Citation: Thomas Andreas, Walpurgis Katja, Thevis Mario (2024). Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples. Journal of mass spectrometry : JMS. DOI: 10.1002/jms.4996

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.